CA2374117A1 - Novel formulations comprising lipid-regulating agents - Google Patents
Novel formulations comprising lipid-regulating agents Download PDFInfo
- Publication number
- CA2374117A1 CA2374117A1 CA002374117A CA2374117A CA2374117A1 CA 2374117 A1 CA2374117 A1 CA 2374117A1 CA 002374117 A CA002374117 A CA 002374117A CA 2374117 A CA2374117 A CA 2374117A CA 2374117 A1 CA2374117 A1 CA 2374117A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- lipid
- excipient
- fenofibrate
- regulating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Abstract
The present invention is directed to a solid formulation comprising the mixture of a lipid-regulating agent and an excipient, in which said agent and said excipient form a eutectic mixture.
Description
Novel Formulations Comprising Lipid-Regulating Agents Field of the Invention The present invention relates to novel formulations comprising lipid-regulating agents.
Background of the Invention 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S.
Patent No. 4,895,726. U.S. Patent No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant.
U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
WO 00172829 CA 02374117 2001-11-15 pCT/US00/14109 European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granules thus produced are dried.
PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon. The carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
Sheu, M. T., et al, Int. J. Pharma. 103 (1994) 137-146, reported that it is possible that the enhancement of dissolution rate by PEG 6000 might arise from the reduction of particle size and/or increase in wettability.
Palmieri, G. F., Pharma Sciences 6 (1996) 188-194, reported that drug solid solutions are formed when the amount of fenofibrate in the powder is below 150, and that drug solubility is increased by the formation of solid dispersion, particularly for the ratio of 90:10 carrier: drug.
Gemfibrozil is another member of the fibrate class of lipid-regulating agents. U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach.
The first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative, and the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth)acrylate copolymer prior to admixture with the first granulation. The first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.
U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members. U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as prevastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
It is an object of the present invention to provide formulations of lipid-regulating agents having enhanced bioavailability when compared to commercially available formulations.
Summary of the Invention The present invention is directed to a solid formulation comprising the mixture of a lipid-regulating agent and an excipient, such as polyethylene glycol, in which said agent and said excipient form a eutectic mixture.
The size reduction obtained through the preparation of a dispersion is usually difficult to obtain. However, by using a fusion technique or solvent evaporation technique, a dispersion of crystalline lipid-regulating agent is prepared in the excipient such that said agent and said excipient form a eutectic mixture. The resulting formulation results in an increase in drug solubility and oral bioavailability, and an improved dissolution rate.
The formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into hard gelatin shells or capsules or compressed into tablets for administration, or administered by other means obvious to those skilled in the art.
WO 00/72$29 CA 02374117 2001-11-15 pCT/US00/14109 Brief Description of the Drawings Figure 1 is a graph showing the plasma concentration in fed dogs of the formulation of Example 1 and a reference 5 compound.
Detailed Description of the Invention The bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No.
4,739,101, both herein incorporated by reference.
The composition comprising the lipid-regulating agent and the excipient in a ratio such that the melting point of both the lipid regulating agent and the excipient is reduced to a single value lower than the melting point of either component is first determined. This composition, i.e. the composition at which the two components exhibit a single melting point, is called the eutectic mixture. A
composition of the lipid-regulating agent and the excipient, ranging from about 0.5% (w/w) to about loo higher than the eutectic mixture, is then heated to a sufficient temperature to obtain a clear solution. The solution is then cooled until a solid mass is formed. As an alternate method, these components at the above mentioned composition range may be dissolved in a suitable solvent to obtain a clear solution.
In this latter case, it is necessary to remove the solvent to obtain the solid mass. The solid mass may then be ground, sized and optionally formulated into an appropriate delivery system.
The delivery system of the present invention results in increased dissolution rate and bioavailability, and improved dissolution rate of the lipid-regulating agent.
WO 00/72829 CA 02374117 2001-11-15 pCT~S00/14109 The term "eutectic mixture" refers to a two phase crystalline system that has a melting point that is lower than that of either pure component of the mixture. The presence of a eutectic mixture can be determined by thermal analysis and powder x-ray diffractometry.
Suitable excipients include, for example, polyethylene glycol (PEG), pentaeythritol, pentaeythritol tetraacetate, succinic acid, urea, polyoxyethylene stearates, and poly-s-caprolactone, or more preferably, PEG.
If a solvent evaporation technique is used, the suitable solvents include, for example, methanol-water, ethanol-water, or other water-miscible organic solvent in which the lipid-regulating agent and the polymers have appreciable solubility.
Other pharmaceutically-acceptable excipients may be added to the formulation prior to forming the desired final product.
Suitable excipients include, for example, lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, or disintegrants that might be needed to prepare a capsule or tablet.
The resulting composition comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into capsules or made into tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The said composition can be used to improve the oral bioavailability and solubility of said lipid-regulating agent.
The invention will be understood more clearly from the following non-limiting representative examples:
Background of the Invention 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S.
Patent No. 4,895,726. U.S. Patent No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant.
U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
WO 00172829 CA 02374117 2001-11-15 pCT/US00/14109 European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granules thus produced are dried.
PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon. The carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
Sheu, M. T., et al, Int. J. Pharma. 103 (1994) 137-146, reported that it is possible that the enhancement of dissolution rate by PEG 6000 might arise from the reduction of particle size and/or increase in wettability.
Palmieri, G. F., Pharma Sciences 6 (1996) 188-194, reported that drug solid solutions are formed when the amount of fenofibrate in the powder is below 150, and that drug solubility is increased by the formation of solid dispersion, particularly for the ratio of 90:10 carrier: drug.
Gemfibrozil is another member of the fibrate class of lipid-regulating agents. U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach.
The first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative, and the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth)acrylate copolymer prior to admixture with the first granulation. The first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.
U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.
Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members. U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as prevastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
It is an object of the present invention to provide formulations of lipid-regulating agents having enhanced bioavailability when compared to commercially available formulations.
Summary of the Invention The present invention is directed to a solid formulation comprising the mixture of a lipid-regulating agent and an excipient, such as polyethylene glycol, in which said agent and said excipient form a eutectic mixture.
The size reduction obtained through the preparation of a dispersion is usually difficult to obtain. However, by using a fusion technique or solvent evaporation technique, a dispersion of crystalline lipid-regulating agent is prepared in the excipient such that said agent and said excipient form a eutectic mixture. The resulting formulation results in an increase in drug solubility and oral bioavailability, and an improved dissolution rate.
The formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into hard gelatin shells or capsules or compressed into tablets for administration, or administered by other means obvious to those skilled in the art.
WO 00/72$29 CA 02374117 2001-11-15 pCT/US00/14109 Brief Description of the Drawings Figure 1 is a graph showing the plasma concentration in fed dogs of the formulation of Example 1 and a reference 5 compound.
Detailed Description of the Invention The bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No.
4,739,101, both herein incorporated by reference.
The composition comprising the lipid-regulating agent and the excipient in a ratio such that the melting point of both the lipid regulating agent and the excipient is reduced to a single value lower than the melting point of either component is first determined. This composition, i.e. the composition at which the two components exhibit a single melting point, is called the eutectic mixture. A
composition of the lipid-regulating agent and the excipient, ranging from about 0.5% (w/w) to about loo higher than the eutectic mixture, is then heated to a sufficient temperature to obtain a clear solution. The solution is then cooled until a solid mass is formed. As an alternate method, these components at the above mentioned composition range may be dissolved in a suitable solvent to obtain a clear solution.
In this latter case, it is necessary to remove the solvent to obtain the solid mass. The solid mass may then be ground, sized and optionally formulated into an appropriate delivery system.
The delivery system of the present invention results in increased dissolution rate and bioavailability, and improved dissolution rate of the lipid-regulating agent.
WO 00/72829 CA 02374117 2001-11-15 pCT~S00/14109 The term "eutectic mixture" refers to a two phase crystalline system that has a melting point that is lower than that of either pure component of the mixture. The presence of a eutectic mixture can be determined by thermal analysis and powder x-ray diffractometry.
Suitable excipients include, for example, polyethylene glycol (PEG), pentaeythritol, pentaeythritol tetraacetate, succinic acid, urea, polyoxyethylene stearates, and poly-s-caprolactone, or more preferably, PEG.
If a solvent evaporation technique is used, the suitable solvents include, for example, methanol-water, ethanol-water, or other water-miscible organic solvent in which the lipid-regulating agent and the polymers have appreciable solubility.
Other pharmaceutically-acceptable excipients may be added to the formulation prior to forming the desired final product.
Suitable excipients include, for example, lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, or disintegrants that might be needed to prepare a capsule or tablet.
The resulting composition comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into capsules or made into tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The said composition can be used to improve the oral bioavailability and solubility of said lipid-regulating agent.
The invention will be understood more clearly from the following non-limiting representative examples:
Example 1 Fenofibrate and PEG in a ratio of 15:85 was heated to about 85°C until a clear solution was obtained. The solution was then cooled over an ice bath resulting in the formation of a solid mass. The resulting dry solid mass was then ground and sized through a 60-100 mesh screen. 446.7 mg. of the granular formulation (containing 67 mg. fenofibrate) was filled into individual capsules.
Example 2 Mixtures of a statin and PEG are prepared and the melting points of these mixtures are determined to locate the eutectic composition. Then the statin and PEG in a ratio that is preferably less than the eutectic composition or to about 10% higher than the eutectic composition is melted to obtain a clear solution, then the solution is cooled over ice bath to form a solid mass. This solid mass is ground and sifted between 60-100 mesh and filled into capsules to contain the appropriate desired dose.
Example 2 Mixtures of a statin and PEG are prepared and the melting points of these mixtures are determined to locate the eutectic composition. Then the statin and PEG in a ratio that is preferably less than the eutectic composition or to about 10% higher than the eutectic composition is melted to obtain a clear solution, then the solution is cooled over ice bath to form a solid mass. This solid mass is ground and sifted between 60-100 mesh and filled into capsules to contain the appropriate desired dose.
Example 3 Capsules prepared by the process described in Example 1, and from a commercial fenofibrate composition, Lipanthyl 67M (Groupe Fournier) (Reference), were administered to a group of dogs at a dose of 67 mg fenofibrate/dog. The plasma concentrations of fenofibric acid were determined by HPLC. Concentrations were normalized to a 6.7 mg/kg dose in each dog. Figure 1 presents the resulting data in graph form. The results provided as mean ~ SD, n=3, were as follows Lipanthyl 67M (Reference):
Cmax = 2.83 ~ 1.40 mcg/ml Tmax = 1.7 + 0.6 hr t1/2 = 14.5 hr AUC (0-24) - 16.36 ~ 6.93 mcg~hr/ml Capsule of Example 1:
Cmax = 5.20~ 1.15 mcg/ml Tmax = 1.3 + 0.6 hr t1/2 = 10.8 hr AUC relative to Reference = 149.08%
Cmax = 2.83 ~ 1.40 mcg/ml Tmax = 1.7 + 0.6 hr t1/2 = 14.5 hr AUC (0-24) - 16.36 ~ 6.93 mcg~hr/ml Capsule of Example 1:
Cmax = 5.20~ 1.15 mcg/ml Tmax = 1.3 + 0.6 hr t1/2 = 10.8 hr AUC relative to Reference = 149.08%
Claims
Claims 1. A composition comprising the mixture of a lipid-regulating agent and an excipient, in which said agent and said excipient form a eutectic mixture.
2. A composition of claim 1 wherein the lipid-regulating agent is present in the composition in an amount ranging from about 0.5% w/w to about 10% by weight above the eutectic mixture.
3. A composition of claim 1 wherein said lipid-regulating agent is a fibrate.
4. A composition of claim 3 wherein said fibrate is fenofibrate.
5. A composition of claim 1 wherein said lipid-regulating agent is a statin.
6. A composition of claim 5 wherein said statin is prevastatin.
7. A composition of claim 5 wherein said statin is atorvastatin.
8. A composition of claim 1 wherein said excipient is selected from polyethylene glycol, pentaeythritol, pentaeythritol tetraacetate, succinic acid, urea, polyoxyethylene stearates, and poly-.epsilon.-caprolactone.
9. A composition of claim 8 wherein said excipient is polyethylene glycol.
10. A delivery system comprising a composition of claim 1.
11. A delivery system of claim 10 wherein said delivery system is a capsule or tablet.
12. A method of treating hyperlipidemia comprising the administration of a composition of claim 1 to a patient.
13. A method of treating hyperlipidemia comprising the administration of a composition of claim 4 to a patient.
15. A method of treating hyperlipidemia comprising the administration of a composition of claim 11 to a patient.
2. A composition of claim 1 wherein the lipid-regulating agent is present in the composition in an amount ranging from about 0.5% w/w to about 10% by weight above the eutectic mixture.
3. A composition of claim 1 wherein said lipid-regulating agent is a fibrate.
4. A composition of claim 3 wherein said fibrate is fenofibrate.
5. A composition of claim 1 wherein said lipid-regulating agent is a statin.
6. A composition of claim 5 wherein said statin is prevastatin.
7. A composition of claim 5 wherein said statin is atorvastatin.
8. A composition of claim 1 wherein said excipient is selected from polyethylene glycol, pentaeythritol, pentaeythritol tetraacetate, succinic acid, urea, polyoxyethylene stearates, and poly-.epsilon.-caprolactone.
9. A composition of claim 8 wherein said excipient is polyethylene glycol.
10. A delivery system comprising a composition of claim 1.
11. A delivery system of claim 10 wherein said delivery system is a capsule or tablet.
12. A method of treating hyperlipidemia comprising the administration of a composition of claim 1 to a patient.
13. A method of treating hyperlipidemia comprising the administration of a composition of claim 4 to a patient.
15. A method of treating hyperlipidemia comprising the administration of a composition of claim 11 to a patient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32318399A | 1999-05-28 | 1999-05-28 | |
| US09/323,183 | 1999-05-28 | ||
| PCT/US2000/014109 WO2000072829A1 (en) | 1999-05-28 | 2000-05-23 | Novel formulations comprising lipid-regulating agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2374117A1 true CA2374117A1 (en) | 2000-12-07 |
Family
ID=23258077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002374117A Abandoned CA2374117A1 (en) | 1999-05-28 | 2000-05-23 | Novel formulations comprising lipid-regulating agents |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1183017A1 (en) |
| JP (1) | JP2003500439A (en) |
| CA (1) | CA2374117A1 (en) |
| MX (1) | MXPA01012225A (en) |
| WO (1) | WO2000072829A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| EP1756039B1 (en) * | 2004-05-14 | 2012-10-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| GB2441499B (en) * | 2006-09-08 | 2011-09-14 | Jasin El Sammadoni | Slimming Spray |
| SI2200588T1 (en) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| US8722094B2 (en) | 2008-03-11 | 2014-05-13 | Aska Pharmaceutical Co., Ltd. | Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2157201C3 (en) * | 1970-11-13 | 1974-12-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Improved solid oral administration form of Raubasin |
| IT1180507B (en) * | 1984-06-29 | 1987-09-23 | Roberto Valducci | PROCEDURE FOR THE PREPARATION OF ETOFIBRATE OR SUBSTANCES OF EQUAL OR SIMILAR CHARACTERISTICS, IN MICROGUNULI-DELAY AND PRODUCT OBTAINED WITH SUCH PROCEDURE |
| FR2627696B1 (en) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
| AU671811B2 (en) * | 1991-12-18 | 1996-09-12 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
-
2000
- 2000-05-23 EP EP00937680A patent/EP1183017A1/en not_active Withdrawn
- 2000-05-23 MX MXPA01012225A patent/MXPA01012225A/en not_active Application Discontinuation
- 2000-05-23 WO PCT/US2000/014109 patent/WO2000072829A1/en not_active Application Discontinuation
- 2000-05-23 JP JP2000620941A patent/JP2003500439A/en not_active Withdrawn
- 2000-05-23 CA CA002374117A patent/CA2374117A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01012225A (en) | 2002-08-12 |
| WO2000072829A1 (en) | 2000-12-07 |
| EP1183017A1 (en) | 2002-03-06 |
| JP2003500439A (en) | 2003-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6465011B2 (en) | Formulations comprising lipid-regulating agents | |
| US6372251B2 (en) | Formulations comprising lipid-regulating agents | |
| US4404183A (en) | Sustained release pharmaceutical composition of solid medical material | |
| EP0142561B1 (en) | Long-acting nifedipine preparation | |
| US6368622B2 (en) | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption | |
| US6383517B1 (en) | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption | |
| WO2000057859A1 (en) | Novel formulations comprising lipid-regulating agents | |
| KR20100038188A (en) | Novel method for producing dry hydrodispersible pharmaceutical forms | |
| MX2007012124A (en) | Formulations containing fenofibrate and surfacant mixture. | |
| EP1140036A2 (en) | Novel formulations comprising lipid-regulating agents | |
| US6838091B2 (en) | Formulations comprising lipid-regulating agents | |
| JPH0157090B2 (en) | ||
| US6814977B1 (en) | Formulations comprising lipid-regulating agents | |
| US8062664B2 (en) | Process for preparing formulations of lipid-regulating drugs | |
| CA2374117A1 (en) | Novel formulations comprising lipid-regulating agents | |
| JP2004536826A (en) | Stable pharmaceutical composition containing pravastatin | |
| US20020040046A1 (en) | Novel formulations comprising lipid-regulating agents | |
| US7014864B1 (en) | Formulations comprising lipid-regulating agents | |
| CA2531097C (en) | Process for preparing formulations of lipid-regulating drugs | |
| US20060177512A1 (en) | Process for preparing formulations of lipid-regulating drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |